Onyx Pharmaceuticals Out-Licenses Japanese Rights to Proteasome Inhibitors

doi:10.3833/pdr.v2010i8.1387

Pharma Deals Review, Vol 2010, No 8 (2010)

Onyx Pharmaceuticals Out-Licenses Japanese Rights to Proteasome Inhibitors

Heather Cartwright

Abstract

In its second oncology deal in September 2010, Ono Pharmaceutical has licensed the Japanese rights to two promising protease inhibitors for multiple myeloma, one of which is at the NDA stage, from Onyx Pharmaceuticals.

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.